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Introduction
This paper was presented at the 10th European Congress of
Clinical Microbiology and Infectious Diseases (28–31 May
2000, Stockholm, Sweden).
Sepsis can be defined as a systemic response to infection
[1]. The incidence of sepsis worldwide is on the increase.
Sepsis and its sequels are the leading causes of death in
intensive care units. Mortality rates are higher for patients
with pre-existing disease, medical conditions, care in the
intensive care unit, and multiple organ failure [2,3]. Despite
steady improvements in antibiotic therapy and intensive care
management during the past decade, mortality has remained
close to 50%. This high mortality rate has continued to stimu-
late interest in pharmacological agents that might reduce
morbidity and mortality [4–7].
AI = adrenal insufficiency; APACHE = Acute Physiology and Chronic Health Evaluation; ACTH = corticotropin; CI = confidence interval; OR =
odds ratio; SOFA = Sequential Organ Failure Assessment.
Abstract
Introduction The aim of the study was to assess the prognostic importance of basal cortisol
concentrations and cortisol response to corticotropin, and to determine the effects of physiological
dose steroid therapy on mortality in patients with sepsis.
Methods Basal cortisol level and corticotropin stimulation test were performed within 24 hours in all
patients. One group (20 patients) received standard therapy for sepsis and physiological-dose steroid
therapy for 10 days; the other group (20 patients) received only standard therapy for sepsis. Basal cortisol
level was measured on the 14th day in patients who recovered. The outcome of sepsis was compared.
Results Only Sequential Organ Failure Assessment (SOFA) score was found related to mortality,
independent from other factors in multivariate analysis. No significant difference was found between
the changes in the percentage of SOFA scores of the steroid therapy group and the standard therapy
group in survivors, nor between the groups in basal and peak cortisol levels, cortisol response to
corticotropin test and mortality. The mortality rates among patients with occult adrenal insufficiencies
were 40% in the steroid therapy group and 55.6% in the standard therapy group.
Discussion There was a trend towards a decrease in the mortality rates of the patients with sepsis
who received physiological-dose steroid therapy. In the advancing process from sepsis to septic
shock, adrenal insufficiency was not frequent as supposed. There was a trend (that did not reach
significance) towards a decrease in the mortality rates of the patients with sepsis who received
physiological-dose steroid therapy.
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Steroid therapy in patients with sepsis is still controversial.
In the 1960s, stress doses of hydrocortisone for the treat-
ment of sepsis were investigated, but no advantages could
be shown in a double-blind multicenter study [8]. This led
to the discontinuation of steroid replacement therapy for
sepsis. In the 1970s, therapy with pharmacological doses
of glucocorticoids was widely used in patients with sepsis
and septic shock. The most compelling evidence in favor of
corticosteroid treatment was reported by Schumer [9] in
his prospective randomized study of steroid administration
to patients with septic shock. These data indicate that
methylprednisolone (30 mg/kg) or dexamethasone
(3 mg/kg) reduced the mortality rate from 38.4% to 10.5%.
However, later in the mid-1980s, pharmacological doses of
glucocorticoids for the treatment of sepsis were investi-
gated extensively until several clinical trials gave negative
results [10–12]. Moreover, there is some evidence that the
use of high-dose glucocorticoids in sepsis might be
harmful [11].
Many studies have demonstrated that elevated cortisol levels
in sepsis and the degree of elevation are related to the sever-
ity of illness [13]. Basal and corticotropin (ACTH)-stimulated
cortisol levels correlate with the severity of illness, and very
high cortisol levels often signify a poor prognosis [14]. In
sepsis, the hypothalamic–pituitary–adrenal axis is activated
through systemic and neural pathways. Circulating cytokines
such as tumor necrosis factor α, interleukin-1 and interleukin-
6 activate the hypothalamic–pituitary–adrenal axis indepen-
dently and, when combined, have synergistic effects [15].
Sepsis can also cause adrenal insufficiency (AI), which is
associated with increased mortality [16]. In recent years,
several authors have proposed a syndrome of occult AI in
septic shock in the presence of normal or even elevated
serum cortisol concentrations. This hypothesis is based on
many studies investigating the adrenocortical response of
patients with septic shock to 0.25 mg of ACTH. Up to 28%
of seriously ill patients have been suggested to have occult or
unrecognized AI [14]. The prevalence of occult AI (a cortisol
increment after a short ACTH test of less than 9 mg/dl) in
severe sepsis was estimated at about 50% and the 28-day
mortality rate at about 75% [17]. A few studies have indi-
cated that stress doses of hydrocortisone improve hemody-
namics in patients with hyperdynamic septic shock, which is
unresponsive to conventional therapy [18,19]. However, the
use of a physiological dose of steroid in patients with sepsis,
severe sepsis, and septic shock has not yet been completely
evaluated. We therefore performed a placebo-controlled, ran-
domized, double-blind, single-center study.
The aim of this study was to assess basal cortisol concentra-
tions and the cortisol response to ACTH stimulation as well
as their prognostic importance, and also to determine the
effects of the physiological-dose steroid therapy on mortality
in patients with sepsis.
Methods
Study design
The study protocol was approved by the Institutional Review
Board of Erciyes University and informed consent was
obtained from the patients’ relatives. This placebo-controlled,
randomized, double-blind, single-center study was performed
at the Department of Medical Intensive Care Unit and the
Department of Infectious Diseases of Erciyes University
Medical School during a 2-year period (from May 1997 to
April 1999).
Patient selection
Patients over 17 years old and diagnosed with sepsis were
included consecutively in the study. The diagnosis of sepsis
was based on the definition of the American College of Chest
Physicians/Society of Critical Care Medicine Consensus
Conference Report [1]. The severity of illness was classified
according to this definition (Table 1).
Criteria for exclusion from the study were as follows: already
known pre-existing adrenal disease or adrenalectomy, known
malignancies, tuberculosis that might have involved the
adrenal gland, and administration of steroids within the
3 months before the admission. In addition, patients with
burns, hemorrhagic shock or those who had suffered myocar-
dial infarction were not included.
Treatment protocol
Patients enrolled in the study were treated with standard
therapy used in the treatment of sepsis and septic shock. This
therapy could include the following: administration of antibi-
otics, fluid replacement, vasoactive drugs, mechanical ventila-
tory support, and any other form of supportive therapy deemed
necessary by the primary physicians. Soon after the presump-
tive diagnosis of severe sepsis, initial laboratory specimens
were obtained and within 2 hours the patients were random-
ized to treatment with prednisolone or placebo groups. The
treatment groups were determined by a computer-generated
randomization procedure. The steroid therapy group received
prednisolone at a physiological dose. Prednisolone was given
intravenously at 06.00 (5 mg) and 18.00 (2.5 mg) for 10 days.
The standard therapy group received a placebo infusion con-
taining physiological saline solution in an identical manner.
Patients and their primary physicians were blinded as to which
therapy was administered.
Data collection
An ACTH stimulation test was performed with 250 µg of
tetracosactrin (synacthene; Ciba Geigy, Germany) given
intravenously. Blood samples were taken immediately before
the test and at 30 and 60 minutes afterwards. After centrifu-
gation, plasma samples were stored at –20°C until assayed.
ACTH stimulation test was repeated on the 14th day in the
patients who survived. Plasma cortisol concentrations were
determined by radioimmunoassay with a commercially avail-
able kit (ICN Biomedicals, Inc, Costa Mesa, California, USA).Intra-assay coefficients of variation were for control A 7.0%,
control B 5.8%, and control C 5.1%. Inter-assay coefficients
of variation were for control A 7.9%, control B 6.5%, control
C 6.0%. The cortisol response was defined as the difference
between the basal and peak cortisol concentrations. Normal
adrenal function was defined as a plasma cortisol level
(before or at 30 or 60 minutes after the injection of ACTH)
above 20 µg/dl. The cases with peak cortisol levels lower
than 20 µg/dl were considered to be AI [13,20–22]. Occult
AI was defined as an increase in cortisol after a ACTH test of
less than 9 µg/dl (a cortisol response of no more than
9 µg/dl) [17,23,24].
Community-acquired sepsis had its onset within 72 hours of
the patients’ admission to the hospital, whereas hospital-
acquired sepsis began 72 hours or later after admission. The
estimated prognosis of any pre-existing underlying diseases
had been classified according to the classification of
McCabe and Jackson [25].
Observed initial findings that related to disseminated intravas-
cular coagulation, respiratory insufficiency, altered mental
status, and renal, cardiac, and liver failure were noted
[26,27]. The severity of the illness was assessed with the
Acute Physiology and Chronic Health Evaluation II
(APACHE II) scoring system [28]. The Sequential Organ
Failure Assessment (SOFA) score [29] was added to the
study protocol by amendment and retrospectively from the
raw data. Infections were diagnosed according to clinical and
microbiological criteria. Blood samples for cultures were
obtained by the same investigator (O Yildiz) and inoculated
into a standard culture medium (BACTEC 9240). Patients
were evaluated at enrollment and at the 24th hour, and on the
3rd, 7th, 10th, 14th, 21st, and 28th days, and followed for
1 month after discharge from hospital.
Body temperature, respiratory rate, heart rate, blood pres-
sure, the use of vasopressor drugs, urine output, complete
blood counts, urinalysis with microscopic examination, ery-
throcytes sedimentation rate, blood chemistry, prothrombin
time, partial thromboplastin time, fibrinogen, fibrin debranch-
ing product, blood gases, electrocardiogram, and chest
roentgenogram were recorded for each patient individually.
Study endpoints
The primary endpoint of the study was 28-day mortality from
all causes. The secondary endpoint consisted of adverse
occurrences including possible complications of drug therapy
and morbid events such as the progression of initial infection
and the development of secondary infection. Secondary infec-
tion was defined as the identification of a new site of infection
or the emergence of a different organism at the same site,
generally requiring a change in antibiotic management.
All medications given to the patients, any complications, the
duration of hospitalization, the mortality rate, and the causes
of death were recorded and compared between the groups.
We also compared average values of basal cortisol, peak cor-
tisol and cortisol responses to ACTH between survivors and
non-survivors on the first day. Moreover, basal cortisol levels
on the 1st and 14th days were compared in patients who
recovered in each group.
Statistical analysis
Student’s t-test and the Mann–Whitney U multivariate analy-
sis test were used for continuous variables, χ2 and Fisher’s χ2
tests were used for proportions, and logistic regression was
used for effects of factors on mortality. Values are expressed
as means ± SD, odds ratio (OR) and 95% confidence interval
(CI) or proportion.
Results
Description of study population
Forty patients with sepsis, severe sepsis and septic shock
were included in this study. The mean age of patients was
56.5 ± 16.4 years in the standard therapy group and
57.8 ± 17.7 years in the steroid therapy group. There was no
significant difference in demographic characteristics, the
severity of underlying diseases, the APACHE II and SOFA
scores, the median time to hospital and median time to death,
the acquisition of infection, and the sepsis categories
between the groups (Table 2).
The 28-day mortality
There were eight deaths (40%) in the steroid therapy group
and 12 (60%) deaths in the standard therapy group
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Table 1
Consensus conference group definitions of the stages of
sepsis [1]
I. Systemic inflammatory response syndrome (SIRS)
Two or more of the following:
Temperature of more than 38°C or less than 36°C
Heart rate of more than 90/min
Respiratory rate of more than 20/min
White blood cell count of more than 12,000/mm3 or less than 
4000/mm3 or more than 10% immature forms (bands)
II. Sepsis
Systemic inflammatory response syndrome plus a 
culture-documented infection
III. Severe sepsis
Sepsis plus organ dysfunction, hypotension, or hypoperfusion 
(including but not limited to lactic acidosis, oliguria, or acute 
alteration in mental status)
IV. Septic shock
Hypotension (despite fluid resuscitation) plus hypoperfusion 
abnormalitiesCritical Care    June 2002 Vol 6 No 3 Yildiz et al.
Table 2
Characteristics of patients
Variable Steroid therapy group Standard therapy group Total χ² P
All patients 20 (50%) 20 (50%) 40 0.417 0.748
Female 7 (43.8%) 9 (56.3%) 16
Male 13 (54.2%) 11 (45.8%) 24
Mean age (years) (mean ± SD) 57.8 ± 17.7 56.5 ± 16.4 57.1 ± 16.9 0.818
Underlying diseases 11 (40.7%) 16 (59.3%) 27 2.849 0.176
Rapidly fatal – – –
Ultimately fatal 2 (50%) 2 (50%) 4
Nonfatal 9 (39.1%) 14 (60.9%) 23
No underlying diseases 9 (69.2%) 4 (30.8%) 13
APACHE II (mean ± SD) 15.4 ± 5.5 17.9 ± 8.0 16.6 ± 6.9 0.249
Maximum SOFA (mean ± SD) 7.8 ± 3.9 9.3 ± 4.0 8.5 ± 4.0 0.257
Acquisition of infection 0.143 1.000
Community 16 (51.6%) 15 (48.4%) 31
Hospital 4 (44.4%) 5 (55.6%) 9
Sepsis categories 0.456 0.531
Sepsis 8 (57.1%) 6 (42.9%) 14
Severe sepsis 8 (47.1%) 9 (52.9%) 17
Septic shock 4 (44.4%) 5 (55.6%) 9
Positive cultures 2.345 >0.05
Gram-negative infection 4 (36.4%) 7 (63.6%) 11
Gram-positive infection 10 (66.7%) 5 (33.3%) 15
Candida infection 1 (33.3%) 2 (66.7%) 3
Polymicrobial infection 3 (60.0%) 2 (40.0%) 5
Negative cultures 6 (46.2%) 7 (53.8%) 13
Organ failure 16 (47.1%) 18 (52.9%) 34
DIC 5 (45.5%) 6 (54.5%) 11
Laboratory measurements (mean ± SD)
Leukocytes (/mm3) 16,057 ± 12,568 14,781 ± 7,317 0.697
Platelets (/mm3) 183,050 ± 137,983 192,800 ± 127,157 0.324
ESR (mm/h) 69 ± 36 49 ± 33 0.081
CRP (mg/l) 67 ± 16 67 ± 24 0.981
Fibrinogen (mg/dl) 814 ± 394 434 ± 198 0.002
Median stay in hospital (days) 14 13 0.406
(95% CI 11.09–20.08) (95% CI 10.13–16.37)
Median time to death (days) 5 5.5 0.496
(95% CI, 2.55–8.20) (95% CI, 2.19–13)
Non-survivors 8 (40%) 12 (60%) 20 1.600* 0.343
Survivors 12 (60%) 8 (40%) 20
*Fisher’s χ2 test. CI, confidence interval; DIC, disseminated intravascular coagulation; ESR, erythrocytes sedimentation rate.(P = 0.343). The mortality rate in the patients with hospital-
acquired sepsis was higher than that in the patients with com-
munity-acquired sepsis in both groups, but this difference was
not statistically significant. The relationship between mortality
and age, the presence of an underlying disease, vasopressor
and steroid therapy, and APACHE II and SOFA scores was
assessed. Age, the presence of an underlying disease, steroid
therapy, basal plasma cortisol levels, and cortisol response to
ACTH below 9 µg/dl were not associated with mortality.
Although a univariate analysis found vasopressor therapy (OR
4.64, 95% CI 1.02–21.00), APACHE II (OR 1.18, 95% CI
1.04–1.34) and maximum SOFA (OR 1.63, 95% CI
1.23–2.16) to be effective on mortality, only the SOFA score
was found related to mortality, independently of other factors
(OR 2.09, 95% CI 1.01–4.30) in a multivariate analysis (Fig. 1
and Table 3).
Variations of treatment effects on the 28-day mortality
among subgroups
The mortality rates among patients with a cortisol level over
60 µg/dl were 29% (2 of 7) in the steroid therapy group and
78% (7 of 9) in the standard therapy group (χ2 = 3.874,
P = 0.126). Although there was an increase in the level of
basal cortisol in patients with sepsis, 14 of 40 patients (35%)
had occult AI. The mortality rates in patients with occult AI
were 40% (2 of 5) in the steroid therapy group and 55.6% (5
of 9) in the standard therapy group, respectively (χ2 = 0.311,
P = 1). Only one patient had both basal and peak cortisol
levels lower than 20 µg/dl; this patient was in the standard
therapy group and died on the 7th day of treatment. This case
was accepted as adrenal failure. A comparison of mortality
rates for basal cortisol and cortisol responses to ACTH in both
groups is shown in Figure 1. The median time to death was
5 days (95% CI 2.55–8.20) in the steroid therapy group and
5.5 days (95% CI 2.19–13) in the standard therapy group
(P = 0.496). The reason for death in all patients was attributed
to sepsis. The median stay in hospital was 14 days (95% CI
11.09–20.08) in the steroid therapy group and 13 days (95%
CI 10.13–16.37) in the standard therapy group (P = 0.406).
Sepsis-related organ dysfunction
Organ dysfunction and failure rates of the patients on admis-
sion were 40% and 45% in the steroid therapy and the stan-
dard therapy groups, respectively (Table 4). No statistically
significant difference was found between the changes in the
percentage of SOFA scores of the steroid therapy group
(43.1 ± 26.5%) and the standard therapy group
(45.4 ± 12.7%) in survivors (P = 0.624).
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tality (%)Cortisol levels and cortisol responses to ACTH
Basal and peak cortisol levels and cortisol responses to
ACTH in the steroid therapy group were not significantly dif-
ferent from those in the standard therapy group (Table 5). The
average values of basal cortisol, peak cortisol and cortisol
responses to ACTH in survivors and non-survivors in both
groups for the first day are shown in Table 3. There was no
significant difference between the values for survivors and
non-survivors. The mean basal cortisol level was
47.6 ± 26.9 µg/dl on the first day in all survivors and
17.2 ± 8.6 µg/dl on the 14th day in patients who recovered
(P = 0.0003). In the steroid therapy group, the mean basal
cortisol level was 52.5 ± 30.5 µg/dl on the first day and
17.6 ± 10.3 µg/dl on the 14th day (P = 0.003). In the stan-
dard therapy group, the mean basal cortisol level was
40.3 ± 19.9 µg/dl on the first day and 16.4 ± 4.6 µg/dl on the
14th day (P = 0.028) (Table 6).
Adverse events
There were no adverse effects due to steroid therapy. Only
one patient, in the standard therapy group, had a secondary
infection.
Discussion
Sepsis is a severe and life-threatening disease. Septic shock
is associated with a mortality rate of more than 50%. Despite
improvements in the overall management of such patients,
including intensive fluid resuscitation, broad-spectrum antibi-
otic therapy, and life-support devices, mortality rates have not
improved during the past decade [4]. In this randomized,
double-blind study of the physiological dose of intravenous
prednisolone or placebo in the treatment of sepsis, we
observed an important difference in mortality rates between
both groups. The mortality rates were 40% in the steroid
therapy group and 60% in the standard treatment group.
There was a trend towards a decrease in the mortality rate of
the patients with sepsis who received physiological-dose
steroid therapy. However, the differences were not statisti-
cally significant (P = 0.343). Several factors were suspected
to be associated with mortality in sepsis [30,31]. Annane et
al. [17] reported that SOFA score, high plasma cortisol levels
and weak response of cortisol to ACTH were also associated
with mortality. However, we found that only SOFA score was
related to mortality, independently of other factors (OR 2.07,
95% CI 1.02–4.22) in the multivariate analysis.
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Table 3
Average values (means ± SD) of basal cortisol, peak cortisol, cortisol responses to corticotropin, APACHE II and maximum SOFA
scores according to survivors and non-survivors in both groups on the first day
Steroid therapy group Standard therapy group
Non-survivors Survivors Non-survivors Survivors
Variable (n = 8) (n = 12) P (n = 12) (n = 8) P
Basal cortisol level (µg/dl) 44.4 ± 24.8 52.5 ± 30.5 0.536 60.5 ± 34.7 40.3 ± 19.9 0.154
Peak cortisol level (µg/dl) 73.1 ± 35.1 79.2 ± 33.5 0.699 80.7 ± 45.9 60.1 ± 25.7 0.265
Cortisol response (µg/dl) 28.7 ± 22.1 21.2 ± 32.7 0.579 16.3 ± 24.6 18.2 ± 16.3 0.835
APACHE II score 17.6 ± 4.5 13.8 ± 5.8 0.130 21 ± 7.9 13.3 ± 6 0.024
Maximum SOFA score 10.6 ± 3.2 5.9 ± 3.3 0.009 11.4 ± 2.9 6 ± 3.3 0.003
APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment.
Table 4
Organ failure in groups at baseline
Steroid Standard 
therapy therapy 
Condition group group Total
Renal failure 6 (50%) 6 (50%) 12
Liver failure 9 (52.9%) 8 (47.1%) 17
Altered mental status 10 (38.5%) 16 (61.5%) 26
DIC 5 (45.5%) 6 (54.5%) 11
Cardiac failure 0 (0%) 2 (100%) 2
Respiratory failure 2 (28.6%) 5 (71.4%) 7
DIC, disseminated intravascular coagulation.
Table 5
Average values (means ± SD) of basal cortisol, peak cortisol




Variable (n = 20) (n = 20) P
Basal cortisol level (µg/dl) 49.3 ± 28 52.4 ± 30.8 0.737
Peak cortisol level (µg/dl) 76.8 ± 33. 3 72.5 ± 39.6 0.712
Cortisol response (µg/dl) 24.2 ± 28.5 17.1 ± 21.2 0.376Briegel et al. [19] showed that stress doses of hydrocorti-
sone reduce the time for the reversal of shock, the number of
organ system failures, and the length of mechanical ventila-
tion in patients with septic shock. This finding underlines the
fact that an impaired adrenocortical function contributes to
vascular hyporesponsiveness in septic shock. In contrast to
other studies, our study was performed in patients with
sepsis, severe sepsis and septic shock with the use of physi-
ological-dose prednisolone with or without vasopressor
support. Because the administration of prednisolone does
not affect the circadian adrenocortical patterns and the
results of an ACTH stimulation test in adults, we preferred to
use this drug [32]. In this study we did not completely evalu-
ate the effect of the steroid on patients with vasopressor-
dependent septic shock. However, in a few patients, a
physiological dose of prednisolone reduces the time for the
reversal of shock as defined by the cessation of vasopressor
therapy.
It is known that the plasma cortisol level increases in critical
illnesses and that basal cortisol levels have a positive correla-
tion with severity of illness and prognosis. However, some
investigators [16,23,33–35] showed that patients with sepsis
and high baseline cortisol levels had a lower cortisol
response to the ACTH stimulation test. Our entire study
group had higher mean random basal and stimulated cortisol
levels than those seen in outpatients. The difference between
the basal cortisol levels on the 1st and 14th days in patients
who recovered was statistically significant (P < 0.0001)
(Table 5). We have also shown that basal cortisol levels cor-
relate with the severity of the illness, and that very high corti-
sol levels signify a poor prognosis in the standard therapy
group (Fig. 1).
Clinically significant AI is unusual in outpatients. The studies
of adrenal function in critically ill patients report conflicting
incidences of AI ranging from 0% to 28% [35–37]. Our
results show a low incidence of AI in septic patients. One of
our 40 patients had abnormal basal and peak cortisol levels
(less than 20 µg/dl) and died. This condition was evaluated
as AI. In the advancing process from sepsis to septic shock,
we concluded that AI was not so frequent as supposed.
In recent years, several authors have proposed a syndrome of
occult AI in septic shock in the presence of normal or even
elevated serum cortisol concentrations. Annane et al. [17]
reported that 50% of patients with severe sepsis had occult
AI. In the present study, 14 (35%) of the 40 patients had a
subnormal cortisol response (occult AI). Five patients in the
steroid treatment group had an inadequate cortisol response;
two of them died. However, five of nine patients in the stan-
dard treatment group who showed inadequate cortisol
response died. No statistical differences were observed in
mortality rates between the patients who had occult AI (χ2 =
0.311, P = 1) (Fig. 1).
In conclusion, a physiological dose of intravenous pred-
nisolone had a tendency towards a decrease in mortality in
the patients with sepsis, but the difference between the two
groups was not significant. Because our study had a small
sample size and showed heterogeneity in population in terms
of clinical severity, treatment with physiological-dose steroid
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